RWE results – alk

REACT results video

Learn more about the valuable insights from REACT – the first major study to report within the REWEAL programme.

Click to watch video
Time to REACT in AIT

5 Key results
Results from REACT, the first major study within the REWEAL programme. It's time to REACT in AIT.
5 Key results

Potential new AIT benefits
Beyond relevant outcomes in allergic rhinitis (AR) and asthma, the REACT study also revealed potential new findings related to allergy immunotherapy (AIT), such as reduced risk of pneumonia and hospitalisations. Read more here.
Potential new benefits

Effectiveness of AIT in asthma
The REACT study demonstrated the long-term benefits of allergy immunotherapy (AIT) for patients with allergic rhinitis (AR) and pre-existing asthma, across several clinically relevant asthma outcomes. Read more here.
Effectiveness of AIT in asthma

The REACT study cohort
The REACT study included a total of 92,048 patients with allergic rhinitis (AR) with or without asthma. Half of the cohort was treated with allergy immunotherapy (AIT). Read more to learn about the characteristics of these real-life patients.
The REACT cohort

Long-term effectiveness of allergy immunotherapy
By applying high scientific standards and rigorous methodology, the REACT study demonstrated that allergy immunotherapy (AIT) can have long-term benefits for patients in the real world. Read more here.
Long-term effectiveness of AIT

Understanding allergy immunotherapy utilisation in the United States
AIT is available to many Americans suffering from AR, but before this study, only limited evidence existed on both the burden of disease in patients receiving AIT, as well as the economic patterns behind the initiation of AIT.
AIT in the US

Impact of respiratory allergy on sleep
Allergic respiratory diseases such as AR and AA are known to have a negative impact on sleep and daytime functioning. Read more about our findings of the impact.
Impact on sleep